8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Apr 15, 2026·SEC
Wave Life Sciences Ltd.(WVE)Earnings, Financials & Key Ratios
WVE•NASDAQ
$5.75
Price updated Jun 25, 2026
AboutWave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.Show more
- Revenue$43M-60.5%
- EBITDA-$207M-103.0%
- Net Income-$204M-110.7%
- EPS (Diluted)-1.21-72.9%
- Gross Margin79.28%-20.7%
- EBITDA Margin-483.37%-414.6%
- Operating Margin-504.09%-394.5%
- Net Margin-478.33%-434.0%
- ROE-55.56%+28.7%
WVE Price & Volume
Wave Life Sciences Ltd. (WVE) stock price & volume — 10-year historical chart
Loading chart...
Milestone Volatility Masks Clinical Pipeline Development Risks
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial Position:Healthy
Cash Flow:Burning
Primary Risk:Clinical milestone dependency
"Wave Life Sciences operates a high-intensity R&D model that remains entirely dependent on lumpy, milestone-driven collaboration revenue to offset substantial quarterly operating losses. While the company has successfully bolstered its liquidity to $544.6M as of 2026Q1, the lack of consistent commercial product revenue and persistent negative free cash flow create significant long-term execution risk. Investors should monitor the company's ability to translate its PRISM platform progress into sustainable cash generation before the current cash runway is exhausted by ongoing R&D expenditures exceeding $47M per quarter."
Verdict Logic
while the company maintains a strong liquidity position of $544.6M, the lack of consistent revenue and the high risk of clinical milestone dependency warrant a cautious approach until operational scale is achieved.
WVE Growth Metrics
Wave Life Sciences Ltd. (WVE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years75.75%
5 Years16.31%
3 Years127.08%
TTM-31.58%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-63.44%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-26.19%
Return on Capital
10 Years-85.67%
5 Years-87.8%
3 Years-68.37%
Last Year-54.9%
WVE Recent Earnings
Wave Life Sciences Ltd. (WVE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Apr 28, 2026Metric
Actual
Est
EPS
$0.13+61.8%
$0.34
Rev
$38M+352.6%
$8M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.30-7.1%
$0.28
Rev
$17M+7.4%
$16M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.32-6.7%
$0.30
Rev
$8M-53.5%
$16M
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.31-6.9%
$0.29
Rev
$9M-11.7%
$10M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.13vs $0.34+61.8% | $38Mvs $8M+352.6% |
| Q1 2026 | Feb 26, 2026 | $0.30vs $0.28-7.1% | $17Mvs $16M+7.4% |
| Q4 2025 | Nov 10, 2025 | $0.32vs $0.30-6.7% | $8Mvs $16M-53.5% |
| Q3 2025 | Jul 30, 2025 | $0.31vs $0.29-6.9% | $9Mvs $10M-11.7% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Wave Life Sciences Ltd. (WVE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.75 | $1.11B | -4.75 | -60.55% | -478.33% | -55.56% | — | |
| $16.02 | $1.69B | -2.25 | 15.58% | 2.98% | 4.89% | — | |
| $78.34 | $12.95B | -32.92 | 33.87% | -30.87% | -58.57% | — | |
| $79.27 | $11.17B | -6497.54 | 23258.15% | -48.38% | -55.09% | — | |
| $16.03 | $1.8B | -4.21 | 16.92% | -597.04% | -57.27% | — | |
| $33.93 | $3.49B | -41.89 | 120.01% | -49.17% | -5.89% | — |
Compare WVE vs Peers
Wave Life Sciences Ltd. (WVE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
WVE SEC Filings & Documents
Wave Life Sciences Ltd. (WVE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when WVE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
WVE Frequently Asked Questions
Wave Life Sciences Ltd. (WVE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Wave Life Sciences Ltd.'s revenue?
Wave Life Sciences Ltd. (WVE) reported $71.8M in revenue for fiscal year 2025.
How fast is Wave Life Sciences Ltd. growing?
Wave Life Sciences Ltd. (WVE) saw revenue decline by 60.5% over the past year.
Is WVE profitable?
Wave Life Sciences Ltd. (WVE) reported a net loss of $183.6M for fiscal year 2025.
Dividend & Returns
What is WVE's return on equity?
Wave Life Sciences Ltd. (WVE) has a return on equity (ROE) of -55.6%. Negative ROE indicates the company is unprofitable.
What is Wave Life Sciences Ltd.'s free cash flow?
Wave Life Sciences Ltd. (WVE) had negative free cash flow of $183.3M in fiscal year 2025, likely due to heavy capital investments.